Citations

Clear

1526 citation(s) found for "Sun, C".

Differential effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
Su, L. Joseph , Zhang, Jiahao , Jiang, Nanhui, Yang, Jie , Qin, Xie, Huang, Rong , Feng, Ying , Lu, Qiaofa , Peng, Zhiyong , su, lianjiu, Li, He , Liu, Fang , Kashani, Kianoush , Sun, Zhongyi

Mayo Clinic

No container title available | September 3, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-57987/v1 Get It

Abstract BackgroundThe effect of angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (ACEI/ARB) on the COVID-19 remains controversial from clinic evidence. MethodsThis is a retrospective, two-center case series of 198 consecutive COVID-19 patients with a history of hypertension. ResultsAmong 198 patients, 58 (29.3%) and 16 (8.1%) were on were on ARB and ACEI, respectively. Patients who were on ARB or ACEI/ARB had a significantly lower rate of severe illness and ARDS when compared with patients treated with ACEI alone or not receiving and RAAS blocker (P<0.05). The Kaplan-Meier survival curve showed that patients with ARB in their antihypertensive regimen had a trend towards a higher survival rate when compared with individuals without ARB (adjusted hazard ratio, 0.27; 95% CI, 0.07-1.02; P = 0.054). The Cox-regression analysis to compared ACEI vs. ARB groups showed a significantly lower mortality rate in the ARB group (adjusted hazard ratio, 0.03; 95% CI, 0.00-0.58; P = 0.02). ConclusionsUsing of ARB was associated with a reduced rate of severe illness and ARDS, indicating their potential protective impact in COVID-19.
Comment on: RTTBD‐like activity in association with hippocampal ictal discharges in patients with temporal lobe epilepsy by Sun et al.
Tatum, William O. , Desai, Nimit

Mayo Clinic

Epileptic Disorders | September 3, 2020 | Volume: 22 | Issue: 4 | Pages: 473-475

10.1684/epd.2020.1178 | PMID 32759094 Get It

Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study
Okonkwo, David O. , Puffer, Ross C. , Puccio, Ava M. , Yuh, Esther L. , Yue, John K. , Korley, Frederick K. , Sun, Xiaoying, Taylor, Sabrina R. , Jain, Sonia , Manley, Geoffrey T. , Boase, Kim, Bullock, Ross, Crawford, Karen , Dikmen, Sureyya, Duhaime, Ann-Christine, Ellenbogen, Richard G. , Feeser, V. Ramana, Ferguson, Adam R. , González, Luis, Gopinath, Shankar P. , Gullapalli, Rao P. , Hemphill, Claude, Hotz, Gillian , Kramer, Joel H. , Kreitzer, Natalie , Levin, Harvey S. , Machamer, Joan , Madden, Christopher , McAllister, Thomas W. , McCrea, Michael , Merchant, Randall E., Noël, Florence, Palacios, Eva , Perl, Daniel P. , Rabinowitz, Miri, Robertson, Claudia S. , Satris, Gabriella, Seabury, Seth A., Sherer, Mark , Stein, Murray , Temkin, Nancy, Toga, Arthur W. , Valadka, Alex B. , Vassar, Mary J. , Vespa, Paul , Zafonte, Ross , Diaz‐Arrastia, Ramon , Wang, Kevin , Mukherjee, Pratik , Markowitz, Amy J. , Adeoye, Opeolu M , Badjatia, Neeraj , Bodien, Yelena G. , Chesnut, Randall Matthew , Corrigan, John D. , Foreman, Brandon , Gardner, Raquel C. , Gaudette, Étienne , Giacino, Joseph T. , Goldman, Dana P. , Lindsell, Christopher J. , Martin, Alastair J. , Nelson, Lindsay D. , Ngwenya, Laura Benjamin , Rosand, Jonathan M. , Sander, Angelle M. , Schnyer, David M. , Stein, Murray B.

Mayo Clinic

Journal of Neurotrauma | August 28, 2020 | Volume: 37 | Issue: 23 | Pages: 2460-2467

10.1089/neu.2020.7140 | PMID 32854584 Get It

Glial fibrillary acidic protein (GFAP) is cleared by the Food and Drug Administration (FDA) to determine need for head computed tomography (CT) within 12 h after mild traumatic brain injury (TBI) (Glasgow Coma Score [GCS] 13–15); S100 calcium-binding protein B (S100B) serves this function in Europe. This phase 1 biomarker cohort analysis of the multi-center, observational Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study compares GFAP's diagnostic performance, measured on a rapid point-of-care platform, against protein S100B to predict intracranial abnormalities on CT within 24 h post-injury across the spectrum of TBI (GCS 3–15). Head CT scan performed in TBI subjects and blood was collected for all consenting subjects presenting to 18 United States level 1 trauma centers. Plasma was analyzed on a point-of-care device prototype assay for GFAP and serum was analyzed for S100B. In 1359 patients with TBI (GCS 3–15), mean (standard deviation [SD]) age = 40.1 (17.0) years; 68% were male. Plasma GFAP levels were significantly higher in CT+ TBI subjects (median = 1358 pg/mL, interquartile range [IQR]: 472–3803) than in CT- TBI subjects (median = 116 pg/mL, IQR: 26–397) or orthopedic trauma controls ( n = 122; median = 13 pg/mL, IQR: 7–20), p < 0.001. Serum S100B levels were likewise higher in CT+ TBI subjects (median = 0.17 μg/L, IQR: 0.09–0.38) than in CT- TBI subjects (median = 0.10 μg/L, IQR: 0.06–0.18), p < 0.001. Receiver operating characteristic curves were generated for prediction of intracranial injury on admission CT scan; area under the curve (AUC) for GFAP was significantly higher than for S100B in the same cohort (GFAP AUC – 0.85, 95% confidence interval [CI] 0.83–0.87; S100B AUC – 0.67, 95% CI 0.64-0.70; p < 0.001). GFAP, measured on a point-of-care platform prototype assay, has high discriminative ability to predict intracranial abnormalities on CT scan in patients with TBI across the full injury spectrum of GCS 3–15 through 24 h post-injury. GFAP substantially outperforms S100B.
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214
Gore, E., Bae, K., Wong, Stephanie M. , Bonner, J., Gaspar, Laurie E., Bogart, J.J. Van, Werner‐Wasik, Maria, Choy, H. , Wong, S., Sun, A. , Schild, Steven E. , Bogart, J.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 7506-7506

10.1200/jco.2009.27.15_suppl.7506 Get It

7506 Background: The incidence of central nervous system (CNS) metastases is high in patients with locally advanced non-small cell lung cancer. Brain as an only site of relapse appears increasingly common as loco-regional and extra-cranial systemic treatment improves. There is not standard agreement as to how to address this risk. Methods: Patients with stage III NSCLC without progression of disease after loco-regional treatment with surgery and/or radiation therapy with or without chemotherapy were eligible. Participants were randomized to prophylactic cranial irradiation (PCI) or observation and stratified by stage (IIIA or B), histology (non-squamous or squamous) and therapy (surgery or no surgery). PCI was delivered once daily at 2Gy per fraction to 30Gy. The primary endpoint of the study was overall survival (OS). Secondary endpoints were disease free survival (DFS) and the impact of PCI on incidence of CNS metastases, neuropsychological function, and quality of life (QoL). Kaplan- Meier estimation with the log-rank test was used for OS and DFS and the logistic regression model was used for calculating the incidence of CNS metastasis. Results: Total accrual was 356 patients of the targeted 1058 between 9/19/02 and 8/30/07. The study was closed early due to slow accrual. 340 patients were evaluable. One year OS (p=0.86, 75.6 % and 76.9% for PCI and observation) and one year DFS (p=0.11, 56.4% and 51.2% for PCI and observation) were not statistically significantly different. However, CNS metastatic rate at 1 year was statistically significantly different with CNS relapse 7.7% vs. 18% for PCI vs. observation (p=0.004). Logistic regression showed that the patients in the observation arm are 2.52 times more likely to develop CNS metastases than those in the PCI arm (odds ratio=2.52, 95% CI=(1.32–4.80)). Conclusions: PCI in patients without progressive disease after loco-regional therapy for III NSCLC significantly decreases the rate of CNS metastases. This study did not show a statistically significant difference in OS or DFS. Forthcoming analysis of the impact of PCI on neuropsychological function and QoL will influence the recommendations regarding the standard use of PCI. No significant financial relationships to disclose.
A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900
Fernández, Hugo F. , Litzow, Mark R. , Luger, S. M., Paietta, Elisabeth, Dewald, G, Rowe, Jacob M. , Lazarus, H M, Tallman, Martin S. , Sun, Zhe , Ketterling, Rhett P.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 7003-7003

10.1200/jco.2009.27.15_suppl.7003 Get It

7003 Background: In younger adults with newly diagnosed acute myeloid leukemia (AML), anthracycline dose intensification during induction may improve complete remission (CR) rates; however, an improvement in overall survival (OS) in a randomized trial has not been demonstrated. This unresolved issue led the ECOG to compare standard dose (SDD) to high-dose daunorubicin (HDD) in induction. Methods: Adult patients with previously untreated AML were randomized to receive either SDD (45 mg/m2/d) or HDD (90 mg/m2/d) each for 3days combined with standard-dose cytarabine (100 mg/m2/d) for 7 days by continuous intravenous infusion. Those achieving a CR were allocated to allogeneic hematopoietic stem cell transplantation (HSCT) or high-dose cytarabine (with or without a single dose of gemtuzumab ozogamicin) prior to autologous HSCT. Intravenous busulfan and cyclophosphamide was the preparative regimen for both allogeneic and autologous HSCT. The primary end point of this study was OS from the time of induction randomization. Results: 633 patients, age 18 to 60 (median 48) years, were entered in this study. There were no differences in patient demographics or disease characteristics between the two groups at presentation. In an intention-to-treat analysis, HDD resulted in a significantly higher CR rate (63.3% vs. 47.7%, p = 0.0003) than SDD. Induction deaths were similar between the two groups (5.4 vs. 5.0%, p = ns). 334 (52.8%) patients entered the consolidation phase. 57.4% of HDD and 48.1% of the SDD patients, received consolidation therapy on study, and 28.7% and 23.1% proceeded to HSCT respectively. Median OS was superior for the HDD (23.7 months) over the SDD (15.1 months) group (p = 0.005). In subgroup analysis, patients with favorable or intermediate-risk cytogenetics or age <55 years benefited from the HDD. Conclusions: We demonstrate for the first time in a prospective randomized trial that intensifying induction therapy through a higher daily anthracycline dose, in the setting of identical intensive consolidation therapy, results in a higher CR rate as well as prolonged OS. In younger AML patients a higher dose of anthracycline in induction should be considered the new standard of care. No significant financial relationships to disclose.
KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype
Zhang, Boyi , Long, Qilai , Wu, Shanshan , Song, Shuling, Xu, Qixia, Liu, Han , Qian, Min , Ren, Xiaohui , Jiang, Jing , Fu, Qiang , Guo, Jianming , Chang, Xing, Campisi, Judith , Kirkland, James L. , Qian, Min, Fu, Qiang, Zhang, Xiaoling , Lam, Eric W.‐F. , Sun, Yu

Mayo Clinic

No container title available | August 17, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-52927/v1 Get It

Abstract Cellular senescence restrains the expansion of neoplastic cells through several layers of regulation, including epigenetic decoration of chromatin structure and functional modulation of bioactive components. Here we report that expression of the histone H3-specific demethylase KDM4 is upregulated in human stromal cells upon cellular senescence. In clinical oncology, upregulated KDM4 and diminished H3K9/H3K36 methylation are correlated with adverse survival of cancer patients post-chemotherapy. Global chromatin accessibility mapping via ATAC-seq and expression profiling through RNA-seq reveal extensive reorganization of chromosomes and spatiotemporal reprogramming of the transcriptomic landscape, events responsible for development of the senescence-associated secretory phenotype (SASP). Selectively targeting KDM4 dampens the SASP of senescent stromal cells and enhances the apoptotic index of cancer cells in the treatment-damaged tumor microenvironment (TME), together prolonging overall survival of experimental animals. Our study supports the dynamic change of H3K9/H3K36 methylation marks during cellular senescence, identifies an unusually permissive chromatin state, unmasks KDM4 as a key modulator of the SASP, and presents a novel therapeutic avenue to manipulate cellular senescence and curtail age-related pathologies.
Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies
Hidaka, Akihisa , Harrison, Tabitha A. , Cao, Yin , Sakoda, Lori C. , Barfield, Richard , Giannakis, Marios , Phipps, Amanda I. , Figueiredo, Jane C. , Zaidi, Syed Hassan Ejaz , Berndt, Sonja I. , Borozan, Ivan , Gallinger, Steven , Gunter, Marc J. , Guinter, Mark A. , Harlid, Sophia , Moreno, Vı́ctor , Nishihara, Reiko , Obón‐Santacana, Mireia , Parfrey, Patrick S. , Slattery, Martha L. , Steinfelder, Robert S. , Wang, Xiaoliang , Woods, Michael O. , Guelpen, Bethany Van , Thibodeau, Stephen N. , Hoffmeister, Michael , Peters, Ulrike , Amitay, Efrat L , Guinter, Mark A , Harlid, Sophia , Hampel, Heather , Moreno, Victor , Ogino, Shuji , Potter, John D , Slattery, Martha L , Um, Caroline Y , Van Guelpen, Bethany , Hoffmeister, Michael , Sun, Wei , Buchanan, Daniel D , Sakoda, Lori C , Cao, Yin , Gunter, Marc J , Harrison, Tabitha A , Hidaka, Akihisa , Wang, Xiaoliang , Obón-Santacana, Mireia , Song, Mingyang , Toland, Amanda Ewart , Amitay, Efrat L. , Chan, Andrew T. , Hampel, Heather , Jenkins, Mark A. , Lin, Yi , Newcomb, Polly A. , Potter, John D. , Um, Caroline Y. , Sun, Wei , Hsu, Li , Buchanan, Daniel D. , Campbell, Peter T.

Mayo Clinic

Cancer Research | August 14, 2020 | Volume: 80 | Issue: 20 | Pages: 4578-4590

10.1158/0008-5472.can-20-0168 | PMID 32816852 Get It

Abstract Protective associations of fruits, vegetables, and fiber intake with colorectal cancer risk have been shown in many, but not all epidemiologic studies. One possible reason for study heterogeneity is that dietary factors may have distinct effects by colorectal cancer molecular subtypes. Here, we investigate the association of fruit, vegetables, and fiber intake with four well-established colorectal cancer molecular subtypes separately and in combination. Nine observational studies including 9,592 cases with molecular subtypes for microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and somatic mutations in BRAF and KRAS genes, and 7,869 controls were analyzed. Both case-only logistic regression analyses and polytomous logistic regression analyses (with one control set and multiple case groups) were used. Higher fruit intake was associated with a trend toward decreased risk of BRAF-mutated tumors [OR 4th vs. 1st quartile = 0.82 (95% confidence interval, 0.65–1.04)] but not BRAF-wildtype tumors [1.09 (0.97–1.22); P difference as shown in case-only analysis = 0.02]. This difference was observed in case–control studies and not in cohort studies. Compared with controls, higher fiber intake showed negative association with colorectal cancer risk for cases with microsatellite stable/MSI-low, CIMP-negative, BRAF-wildtype, and KRAS-wildtype tumors (Ptrend range from 0.03 to 3.4e-03), which is consistent with the traditional adenoma-colorectal cancer pathway. These negative associations were stronger compared with MSI-high, CIMP-positive, BRAF-mutated, or KRAS-mutated tumors, but the differences were not statistically significant. These inverse associations for fruit and fiber intake may explain, in part, inconsistent findings between fruit or fiber intake and colorectal cancer risk that have previously been reported. Significance: These analyses by colorectal cancer molecular subtypes potentially explain the inconsistent findings between dietary fruit or fiber intake and overall colorectal cancer risk that have previously been reported.
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Qu, Moyuan , Tebon, Peyton , Jiang, Xing , Wang, Canran , Zhu, Jixiang , Zhang, Shiming , Öklü, Rahmi , Sengupta, Shiladitya , Sun, Wujin , Khademhosseini, Ali, Khademhosseini, Ali , Oklu, Rahmi , Zhou, Xingwu , Xue, Yumeng

Mayo Clinic

Advanced Science | August 14, 2020 | Volume: 7 | Issue: 19 | Pages: No page available

10.1002/advs.202001447 | PMID 33042756 Get It

AbstractImmunotherapy is a class of promising anticancer treatments that has recently gained attention due to surging numbers of FDA approvals and extensive preclinical studies demonstrating efficacy. Nevertheless, further clinical implementation has been limited by high variability in patient response to different immunotherapeutic agents. These treatments currently do not have reliable predictors of efficacy and may lead to side effects. The future development of additional immunotherapy options and the prediction of patient‐specific response to treatment require advanced screening platforms associated with accurate and rapid data interpretation. Advanced engineering approaches ranging from sequencing and gene editing, to tumor organoids engineering, bioprinted tissues, and organs‐on‐a‐chip systems facilitate the screening of cancer immunotherapies by recreating the intrinsic and extrinsic features of a tumor and its microenvironment. High‐throughput platform development and progress in artificial intelligence can also improve the efficiency and accuracy of screening methods. Here, these engineering approaches in screening cancer immunotherapies are highlighted, and a discussion of the future perspectives and challenges associated with these emerging fields to further advance the clinical use of state‐of‐the‐art cancer immunotherapies are provided.
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy
Werner, Christian K. , Nna, Uchechi J. , Sun, Hanshi, Wilder-Romans, Kari , Dresser, Joseph, Kothari, Ayesha U. , Zhou, Weihua , Yao, Yangyang , Rao, Arvind , Stallard, Stefanie, Bor, Tarik , Debinski, Waldemar, Hegedus, Alexander M. , Morgan, Meredith A. , Venneti, Sriram , Baskin-Bey, Edwina, Spratt, Daniel E. , Colman, Howard , Speers, Corey , Lawrence, Theodore S. , Wahl, Daniel , Bor, Tarik , Hegedus, Alexander M , Colman, Howard , Speers, Corey , Lawrence, Theodore S , Spratt, Daniel E , Kothari, Ayesha U , Werner, Christian K , Koschmann, Carl , Sarkaria, Jann N. , Chinnaiyan, Arul , Eisner, Joel Robert , Strowd, Roy E.

Mayo Clinic

Molecular Cancer Therapeutics | August 12, 2020 | Volume: 19 | Issue: 10 | Pages: 2163-2174

10.1158/1535-7163.mct-20-0095 | PMID 32796101 Get It

Abstract New approaches are needed to overcome intrinsic therapy resistance in glioblastoma (GBM). Because GBMs exhibit sexual dimorphism and are reported to express steroid hormone receptors, we reasoned that signaling through the androgen receptor (AR) could mediate therapy resistance in GBM, much as it does in AR-positive prostate and breast cancers. We found that nearly half of GBM cell lines, patient-derived xenografts (PDX), and human tumors expressed AR at the transcript and protein level—with expression levels overlapping those of primary prostate cancer. Analysis of gene expression datasets also revealed that AR expression is higher in GBM patient samples than normal brain tissue. Multiple clinical-grade antiandrogens slowed the growth of and radiosensitized AR-positive GBM cell lines and PDXs in vitro and in vivo. Antiandrogens blocked the ability of AR-positive GBM PDXs to engage adaptive transcriptional programs following radiation and slowed the repair of radiation-induced DNA damage. These results suggest that combining blood–brain barrier permeable antiandrogens with radiation may have promise for patients with AR-positive GBMs.